We describe the use of remifentanil in a woman with severe pre-eclampsia who presented for emergency caesarean section. Remifentanil was effective in obtunding the hypertensive response to laryngoscopy and intubation. Previous studies have found no significant adverse effects of remifentanil on the neonate. With its short duration of action, the use of this new opioid has several potential advantages in the above setting. Further studies are required to explore the use of remifentanil as an adjunct to obstetric general anaesthesia.
The use of opioids in obstetric anaesthesia can adversely affect the newborn. We describe the use of remifentanil, a new short-acting opioid, in the emergency caesarean section of a woman with severe preeclampsia complicated by thrombocytopenia and abnormal liver function.
CASE HISTORY
A 28-year-old 73 kg woman, gravida 1 para 0, was referred at 27 weeks' gestation. She had been well until her blood pressure had started rising a week before, peaking on the day of referral at 170/105 mmHg. She had also experienced worsening epigastric pain over that time. Along with her hypertension, she was noted to have mild pedal oedema, brisk reflexes and a platelet count of 28x10 9 /l (140-400x10 9 /l). Other laboratory investigations showed a raised white cell count, moderately deranged liver function tests, normal renal function and a normal coagulation screen of APTT 36 (25-40 s), INR 1.2 (0.8-1.2), TCT 15 (10-20s), fibrinogen 4.1 (1.5-4 g/l). She was on a magnesium sulphate (MgSO 4 ) infusion, her serum magnesium level was 1.4 mmol/l (therapeutic level >2 mmol/l).
Fetal ultrasound suggested intrauterine growth retardation, estimating gestation at 21 weeks. In view of the above findings, an emergency caesarean section was planned.
Monitoring in the operating theatre included standard monitoring plus an intra-arterial line and a urinary catheter. The MgSO 4 infusion was continued at 1g/h. After preoxygenation, a remifentanil infusion (20 µg/ml) was commenced initially at 50 ml/h (0.23 µg/kg/min). After about two minutes the rate was increased to 80 ml.h -1 (0.37 µg/kg/min), the patient was induced with thiopentone 450 mg, cricoid pressure applied and 100 mg suxamethonium given. Approximately four minutes after commencement of the remifentanil infusion (after a total dose of 86 µg, or 1.17 µg/kg), the patient was intubated with a size 7.5 endotracheal tube.
At this stage a minimal response to intubation was seen. Pre-induction blood pressure (BP) was 156/93 mmHg and the systolic rose by 15 mmHg at intubation, while the pulse rose from 75 beats per minute pre-induction to 110 beats per minute.
After confirmation of correct tracheal tube placement using capnography, atracurium 25 mg was given. The patient was maintained at end-tidal isoflurane concentrations of 0.3 to 0.8%, and on nitrous oxide, initially as a 50% mixture with oxygen until delivery of the baby, then increased to 66% with 33% oxygen. A small female infant was delivered approximately eight minutes after induction of anaesthesia. At 27 weeks gestation, she was small for gestational age and weighed only 635g. Her Apgar scores were 3, 5 and 10 at 1, 5 and 10 minutes respectively. She required intubation within the first few minutes of delivery, but started breathing spontaneously soon thereafter, the tube still in situ. Immediately after delivery the remifentanil infusion was reduced to 30 ml/h (0.137 µg/kg/min). A total of 10 mg of morphine was subsequently given after delivery of the baby. We infused one litre of normal saline and transfused three units of platelets during the operation. The surgeons commented on the good haemostasis obtained.
Mean BP was in the range of 70 to 85 mmHg throughout the procedure and mean pulse rate ranged from 62 to 88 beats per minute.
At the end of the operation, after stopping the remifentanil infusion, muscle relaxation was reversed using 1.2 mg of atropine and 2.5 mg of neostigmine. The patient was extubated awake and on her side, with a minimal hypertensive response, having resumed spontaneous respirations approximately five minutes after cessation of the remifentanil infusion.
The patient was transferred to the Intensive Care Unit (ICU) for postoperative monitoring. She was alert, haemodynamically stable and maintained good oxygen saturation. Intravenous morphine patientcontrolled analgesia was commenced. The magnesium sulphate infusion was continued over the next 24 hours, maintaining magnesium levels around 1.6 mmol/l.
A further three units of platelets were transfused in ICU and she was discharged from the ICU the following day, having remained stable overnight. The baby was ventilated in the Newborn Unit for 24 hours.
DISCUSSION
Complications of hypertension in pregnancy are still the leading causes of maternal death in the Western world 1 . In this group of patients, neuraxial regional techniques are sometimes contraindicated because of low platelet counts. With general anaesthesia, an accentuated hypertensive response to intubation may cause major morbidity. There are numerous ways of attenuating this response, opioids being widely accepted as effective. In our department, alfentanil 1 to 2 mg is usually used alone, or in combination with MgSO 4 or other antihypertensive agents, such as labetalol or esmolol. The major concern regarding opioid use in pregnancy is placental transfer, and thus neonatal depression. Even alfentanil, with its short half-life, has been shown to have a significant depressant effect on neonatal respiration 2 .
Remifentanil is a new, synthetic, short-acting, µ-opioid receptor agonist which is chemically related to fentanyl and has similar opioid effects 3 . As shown by Egan et al 4 , remifentanil's major advantage over other opioids is that, irrespective of duration of infusion, its blood concentration declines very rapidly following cessation of the infusion-its context sensitive half-life is three minutes. The clearance of remifentanil is eight times greater than that of alfentanil. This is due to its susceptibility to non-specific plasma esterases, thereby eliminating any organ-dependent metabolism. Remifentanil therefore seems a logical choice for use in pregnancy. In their study on the placental transfer of remifentanil, Kan et al 5 concluded that remifentanil crosses the placenta, and causes some maternal sedation, but without any significant adverse effects on either mother or neonate. However the authors do point to limitations of their study due to sampling difficulties.
Scott et al 6 used remifentanil to obtund the response to intubation in a woman with mixed mitral valve disease, asthma and pre-eclampsia. These authors gave a bolus dose of remifentanil of 2 µg/kg (compared with our 1.17 µg/kg) at induction, followed by an infusion of remifentanil at 0.15 µg/kg/ min. After surgical incision, the remifentanil infusion dose was halved to 0.075 µg/kg/min (compared with our 0.137 µg/kg/min) for the remainder of the operation. The neonatal outcome in that case was excellent.
In theatre, we continued the MgSO 4 infusion that had been started by the obstetric team. This infusion was also continued postoperatively. Pre-and postoperative magnesium levels were 1.4 and 1.2 mmol/l respectively. Therapeutic levels aimed at preventing eclampsia are generally accepted to be above 2 mmol/l 7 . Levels successfully used by Ashton et al 7 in attenuating the pressor response to intubation were between 2 and 3 mmol/l. In spite of the levels being subtherapeutic, we did not change the infusion rate of MgSO 4 , but rather selected remifentanil as our mainstay for obtunding the response to intubation. This had good effect.
Remifentanil was chosen for its favourable pharmacokinetics, which were considered to be particularly relevant in our case involving a premature baby with increased susceptibility to respiratory depressants. Her initial unsatisfactory Apgar scores may have resulted from the influence of the general anaesthetic agents. The Apgar scores do not reflect the very short half-life of remifentanil; however, the paediatricians present at the delivery did comment on how "surprisingly vigorous" the baby was under the circumstances.
In choosing the remifentanil dosing, we were guided by computer modelling described by Minto et al 8 , which showed that a remifentanil bolus dose of 1 µg/kg is equipotent to a 200 µg bolus of fentanyl or a 1000 µg bolus of alfentanil, in obtunding the response to intubation. More recently O'Hare et al 9 confirmed that a bolus of 1 µg/kg remifentanil was effective in obtunding the haemodynamic response to intubation, while a 0.5 µg/kg bolus was insufficient and 1.25 µg/kg resulted in an excessive drop in systolic BP in a large proportion of their patients. By continuing the remifentanil infusion throughout the case, we felt we could maintain more stable haemodynamics in an easily titratable manner. Some other potential advantages of using remifentanil in our case are worth noting. Firstly, several studies 3 , have supported the use of remifentanil in the presence of liver or renal dysfunction, where plasma clearance is unaffected. In severe pre-eclampsia, hepatic and renal dysfunction may be present. Secondly a continuous infusion of an opioid is known to reduce the minimum alveolar concentration of inhalation agents 3 . In our case, remifentanil infusion allowed the use of lower than usual concentrations of isoflurane. This may have had some beneficial effect on uterine tone, and thus haemostasis, since volatile agents tend to cause uterine relaxation 10 .
Thirdly, remifentanil is not expensive in New Zealand. We used one $13.50 ampoule of remifentanil for the case, compared with alfentanil which costs $8.76 for 2 mg.
Despite these possible advantages, documented evidence of the effect of remifentanil in obstetric cases is currently inadequate.
In conclusion we present the successful use of remifentanil as an opioid for obtunding the pressor response to intubation in a patient with severe preeclampsia requiring caesarean section under general anaesthesia. Remifentanil has potential advantages in this particular setting and may prove to be a useful and cost effective adjunct to the anaesthetic management of peripartum patients in general. However, due to a lack of experience of this new opioid in obstetric management, further study is required to explore this potentially fruitful area of practice.
